Samples: storage, logs, and the rules nobody reads

The short answer for a solo office

For most non-controlled prescription samples, yes: a solo office may keep manufacturer samples if you can meet the handling bar — a signed request, secure and access-limited storage, tracked lots and expiration dates, and a way to pull a recall fast. For controlled substances and REMS-restricted drugs, the practical answer is no; those move through channels a sample drawer cannot satisfy. The real question is less whether you may than whether one person can run the controls.

That reframing matters because the duties do not shrink just because the practice is small. A sample you cannot account for is a liability, not a convenience, and the sections below sort the samples you can reasonably keep from the ones that belong to a different system entirely.

What a compliant sample cabinet actually requires

Treat the sample cabinet as inventory you are personally accountable for, because in a solo practice you are. Common practice in well-run offices is a locked, access-limited storage area; a log that records what came in, what went to which patient, and what was discarded; scheduled expiry checks with documented disposal; and a fast path to act on a manufacturer recall. Reputable sample programs will not ship without a signed request and a receipt.

The table below sorts the everyday decisions.

Nothing here is exotic; it is ordinary inventory discipline applied by one person instead of a pharmacy department.

Controlled substances are not sampled like other drugs

Controlled substances do not reach a solo office through ordinary sampling. A prescriber's controlled-substance activity is tied to a DEA registration, state licensing, and prescription drug monitoring program queries before prescribing — an accountability chain built around prescriptions and formal dispensing records, not a walk-in drawer 1Ref 1PDMP Training and Technical Assistance Center (2026).Prescription Drug Monitoring Program Training and Technical Assistance Center.State PDMP query mandates and the controlled-substance accountability chain that keeps such drugs out of ordinary office sampling.. That structure is precisely why a rep does not drop off a bag of controlled starter packs.

Buprenorphine shows the shape of it. Since the X-waiver was eliminated, any prescriber with Schedule III authority and a current DEA registration may prescribe it for opioid use disorder, subject to a one-time training attestation — a change in effect as of 2026 2Ref 2Substance Abuse and Mental Health Services Administration (2026).Buprenorphine.Post-X-waiver buprenorphine prescribing by any DEA-registered Schedule III prescriber for OUD, as a prescription pathway rather than a sample.. That is a prescribing pathway, not a sampling one. If you want to start a patient on a controlled medication, that is a prescription: your controlled-substance workflow — your refill policy, your PDMP checks, and how you handle a no-show plus refill request — governs these drugs, not a shelf of starter packs a rep dropped off.

REMS drugs are dispensed through the program, not the closet

Some drugs carry a Risk Evaluation and Mitigation Strategy, or REMS, that dictates how they are dispensed and monitored, which removes them from the sample question entirely. Esketamine, for instance, is given under a REMS that requires certified settings and a period of in-office observation; clozapine's REMS ties continued dispensing to monitoring results 3Ref 3U.S. Food and Drug Administration (2026).Risk Evaluation and Mitigation Strategies (REMS).REMS-restricted drugs (esketamine, clozapine) are dispensed and monitored through the REMS program, not kept as office samples.. You cannot keep these on a shelf as starter samples — the program controls access, not your cabinet.

The practical wrinkle for a solo prescriber is the monitoring. Clozapine's requirements can mean arranging labs without a health system behind you, and long-acting injectables — LAIs in a solo practice — usually run through a buy-and-bill process rather than free sampling. Before you assume you can stock any newer agent, check whether it carries a REMS; the FDA maintains the current list, and a proposed change is never the operative rule until it is final.

If the sample is an injectable

Any injectable sample pulls in infection-control duties even in a low-volume solo office. CDC's core practices for safe healthcare delivery cover hand hygiene, safe injection practices — one needle, one syringe, one patient — single-dose handling, and environmental cleaning, and they apply wherever an injection happens, not only in hospitals 4Ref 4Centers for Disease Control and Prevention (2024).Core Infection Prevention and Control Practices for Safe Healthcare Delivery in All Settings.CDC core infection-prevention and safe-injection practices governing any injectable sample in an outpatient office.. Store each product under its labeled conditions, protect the cold chain where the label requires it, and never pool or reuse single-dose presentations.

This is also where storage failures become clinical events rather than paperwork. A refrigerator that drifts out of range can quietly spoil an injectable, so a solo office that keeps any refrigerated sample needs temperature monitoring and a documented what-if plan for an excursion. If you cannot commit to that, it is a strong signal that injectable samples do not belong in your office.

The billing bright line, and what to do if you cross it

One rule has no exceptions: you may never bill any payer — Medicare, Medicaid, or a commercial plan — for a drug you received free as a sample. A sample has no acquisition cost to pass on, so billing it as though you purchased it is a false claim. Document sample dispensing in the chart as a free sample precisely so it can never be swept into a billable line by mistake.

When cost or access is the real barrier, a documented prior-authorization pathway is the durable fix, not a sample workaround. If you discover a sample was billed, the answer is disclosure, not silence. For a simple overpayment, refund it through the payer's process; for conduct that may implicate federal health-program fraud laws, the OIG maintains a self-disclosure protocol that spells out what a submission must contain 5Ref 5HHS Office of Inspector General (2026).Health Care Fraud Self-Disclosure Protocol.The OIG self-disclosure protocol as the path if a free sample is mistakenly billed to a federal program.. Handling psych-med prior auths cleanly on the front end is how most solo prescribers keep this from ever coming up.

Deciding whether samples are worth it in a solo practice

For a solo prescriber, the honest calculus is whether a starter sample's goodwill is worth the storage, logging, expiry, and recall duties attached to it. Many solo psychiatric and primary-care offices decide the overhead is not worth it and lean instead on manufacturer patient-assistance programs, savings cards, e-prescribing straight to a pharmacy, and prior-authorization pathways — options that leave the inventory risk with someone else while still getting the patient started.

If you do keep samples, keep the set small and boring: a short list of non-controlled agents you actually start often, in a cabinet you can genuinely monitor. How that fits the solo prescriber's schedule matters too — every minute spent reconciling a sample log is a minute not spent in a visit. The right answer is the one you can sustain without a pharmacy tech, because in a solo office there isn't one.